Deborah Morosini
AstraZeneca (United States)(US)Foundation Medicine (United States)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Cancer Genomics and Diagnostics, Cancer Mechanisms and Therapy, DNA Repair Mechanisms, Sarcoma Diagnosis and Treatment
Most-Cited Works
- → Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors(2015)791 cited
- → The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors(2009)528 cited
- → New Routes to Targeted Therapy of Intrahepatic Cholangiocarcinomas Revealed by Next-Generation Sequencing(2014)460 cited
- → An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101(2015)387 cited
- → Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting(2016)302 cited
- → Mechanism of Radiosensitization by the Chk1/2 Inhibitor AZD7762 Involves Abrogation of the G2 Checkpoint and Inhibition of Homologous Recombinational DNA Repair(2010)298 cited
- → Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site(2015)244 cited
- → FGFR1 and NTRK3 actionable alterations in “Wild-Type” gastrointestinal stromal tumors(2016)227 cited
- → EGFR Fusions as Novel Therapeutic Targets in Lung Cancer(2016)140 cited
- → Antiangiogenic and Antimetastatic Activity of JAK Inhibitor AZD1480(2011)112 cited